Trials / Completed
CompletedNCT03784391
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
Effectiveness of Nifurtimox in Patients With Chagas' Disease Based on Data From Patient Medical Records in Argentina: a Retrospective Medical Chart Review Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by parasites mostly transmitted to humans by a bug. They also want to learn how often organs, especially the heart, are affected by the illness in treated and untreated chronic Chaga's patients. In order to find this out medical records of adult and pediatric patients in Argentina will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lampit (Nifurtimox, BAYA2502) | Nifurtimox is a drug already approved in some South American countries since more than 45 years |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2020-04-06
- Completion
- 2020-04-06
- First posted
- 2018-12-21
- Last updated
- 2021-04-08
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT03784391. Inclusion in this directory is not an endorsement.